Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TT4H
|
|||
| Former ID |
DNCL003523
|
|||
| Drug Name |
E6005
|
|||
| Synonyms |
Lotamilast; 947620-48-6; E6005; E-6005; UNII-TO043KKB9C; TO043KKB9C; Methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate; RVT-501; Methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate; Lotamilast [USAN]; SCHEMBL369445; CHEMBL3989967; MolPort-046-033-604; BCP25249; EX-A1382; ZINC113676839; AKOS027337123; SB16962; DB12776; CS-7517; (Methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl(amino)carbonyl)benzoate; HY-12740; AS-52366; Benzoic acid, 4-(((3-(6,7
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20; ICD-9: 691.8, 692.9] | Phase 2 | [1] | |
| Company |
Eisai
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H24N4O5
|
|||
| Canonical SMILES |
CNC1=NC2=CC(=C(C=C2C(=N1)C3=CC(=CC=C3)NC(=O)C4=CC=C(C=C4)C(=O)OC)OC)OC
|
|||
| InChI |
1S/C26H24N4O5/c1-27-26-29-20-14-22(34-3)21(33-2)13-19(20)23(30-26)17-6-5-7-18(12-17)28-24(31)15-8-10-16(11-9-15)25(32)35-4/h5-14H,1-4H3,(H,28,31)(H,27,29,30)
|
|||
| InChIKey |
BBTFKAOFCSOZMB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 947620-48-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 4 (PDE4) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01461941) A Phase 2 Study of E6005 in Patients With Atopic Dermatitis. U.S. National Institutes of Health. | |||
| REF 2 | Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.